Skip to main content
SpringerLink
Log in

The Role of Government and Private Insurers in Guiding and Implementing Pharmacoeconomic Analyses

  • Current Opinion
  • The Role of Government and Private Insurers
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Hillman A, Eisenberg J, Pauly M, et al. Sounding board: avoiding bias in the conduct and reporting of cost—effectiveness research sponsored by pharmaceutical companies. N Engl J Med 1991; 324 (19): 1362–5

    Article  PubMed  CAS  Google Scholar 

  2. Drummond M, Brandt A, Luce B, et al. Standardizing economic evaluation methodologies in health care. Int J Technol Assess Health Care 1993; 9 (1): 26–36

    Article  PubMed  CAS  Google Scholar 

  3. Kassirer JP, Angell M. The journal’s policy on cost—effectiveness analyses. N Engl J Med 1995; 332 (2): 123–5

    Article  Google Scholar 

  4. Commonwealth of Australia. Guidelines for the pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee: including submissions involving economic analysis. Canberra: Department of Health, Housing and Community Services, 1990

    Google Scholar 

  5. Canadian Coordinating Office for Health Technology Assessment (CCOHTA). Guidelines for economic evaluation of pharmaceuticals. 1st ed. Ottawa: CCOHTA, 1994

    Google Scholar 

  6. Udvarhelyi IS, Colditz GA, Rai A, et al. Cost—effectiveness and cost—benefit analyses in the medical literature: are the methods being used correctly? Ann Intern Med 1992; 16 (3): 238–44

    Google Scholar 

  7. US Food and Drug Administration (FDA) Division, Drug Marketing, Advertising and Communications. Principles for the review of pharmacoeconomic promotions [draft guideline]. Rockville (MD): FDA, 1995

    Google Scholar 

  8. Gold MR, Siegel JE, Russell LB, editors. Cost—effectiveness in health and medicine. New York: Oxford University Press, 1996

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Academic Affairs and Bowen Research Center, Indiana University, Bryan Hall 109, Bloomington, Indiana, 47405 1201, USA

    Deborah A. Freund (Vice Chancellor for Academic Affairs)

  2. MEDTAP International, Bethesda, Maryland, USA

    Bryan R. Luce

Authors
  1. Deborah A. Freund
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bryan R. Luce
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Deborah A. Freund.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Freund, D.A., Luce, B.R. The Role of Government and Private Insurers in Guiding and Implementing Pharmacoeconomic Analyses. Pharmacoeconomics 13, 383–387 (1998). https://doi.org/10.2165/00019053-199813040-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-199813040-00001

Keywords

Search

Navigation